Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2003

View Archived Issues

GSK-3beta negatively regulates normal cardiac growth and systolic function in transgenic mice

Avant to conduct phase II trial of TP-10 in women

Accelerated development of viral inhibitor Thiovir for HIV

Beneficial effects of eplerenone in AMI patients with low LVEF

Cytochroma selects drug candidate for treatment of psoriasis

Conivaptan effects on exercise tolerance in patients with chronic heart failure

Clinical trials of MB-7133 begin in liver cancer

Tezosentan: effects on BNP and hemodynamics in acute decompensated heart failure

Carvedilol safe and effective in heart failure patients with Chagas' disease

NSAID + sumatriptan more effective than other therapies for migraine

Sustained pain relief described for subcutaneous DHE in migraine

Daptomycin equieffective to vancomycin and semisynthetic penicillin in skin infections

Phase II results reported for tigecycline in patients with skin and abdominal infections

NicOx to reacquire CINOD rights

Phase II clinical trial of ProCord for spinal cord injury

French authorities recommend against approval of Remodulin

New antiallergic/antiasthmatic agents developed at Rigel

Kissei patents new thyroid hormone receptor ligands

Novel TF/factor VIIa inhibitors under study at Roche

Elan researchers present novel gamma-secretase inhibitors

Indole-based alpha1A-adrenoceptor agonists for urinary incontinence and other uses

Ono scientists prepare and test novel PDE7 inhibitors

Name change for Myriad Proteomics

EluSys receives additional U.S. Department of Defense funds to further develop anthrax drug

Namenda recommended for approval for Alzheimer's disease

Teva and Acorda collaborate on valrocemide

Watson and UCB enter marketing and supply agreement on Oxytrol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...